Evidence map›Paper›PMID 41088988›Full record

ArticleCurrent medicinal chemistry2026

Synthesis, Cytotoxicity Evaluation, and Molecular Dynamics of 4-Thiazolidinone Derivatives: A Potential Path to EGFR-Targeted Anticancer Therapy.

Tomasz Szostek, Dagmara Otto-Slusarczyk, Michał A Dobrowolski, Maciej Wisniewski, Piotr Roszkowski, Daniel Szulczyk

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomasz SzostekChair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0002-4830-1473
Dagmara Otto-SlusarczykChair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0002-3378-4169
Michał A DobrowolskiFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.ORCID 0000-0002-1435-5668
Maciej WisniewskiLaboratory of Bioinformatics and Computational Genomics, Faculty of Mathematics and Information Science, Warsaw, Poland.ORCID 0000-0002-2470-6425
Piotr RoszkowskiFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.ORCID 0009-0001-6391-7233
Daniel SzulczykChair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0003-3083-456X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHeterocyclic compounds remain cornerstones of contemporary drug discovery because their ring-embedded heteroatoms confer adaptable electronics, conformational flexibility, and a broad spectrum of biological activities. The skeleton structure of 4-thiazolidinone is present in many cytotoxically active compounds and is often used in the design of new antitumor agents. This study aimed to synthesize, characterize, and evaluate the anticancer potential of fifteen new (2-imino-4-oxo-1,3-thiazolidin- 5-yl)acetic acid derivatives.

methodsCompounds were synthesized using a consistent synthetic route involving a reaction between a thiourea derivative and maleic anhydride, which formed the thiazolidin- 4-one ring through cyclization. The compounds were then categorized into three sets based on the attached heterocyclic rings (tryptamine, thiazole, and 1,2,4-triazole). The NMR and X-ray analysis followed the synthesis. Apoptotic effects, cell cycle arrest, IL-6 suppression, docking, and dynamics simulations were conducted. Preliminary cytotoxic activity was tested on metastatic colorectal cancer (SW620) and human breast adenocarcinoma (MDA-MB-231) cell lines using the MTT assay.

resultsCompounds 5, 6, and 7 demonstrated notable selectivity indexes (4.73, 2.42, 4.16, respectively) and were further investigated for their mechanisms of action, revealing pro-apoptotic properties and the ability to induce cell cycle arrest. Additionally, compound 5 inhibited IL-6 secretion by 76%. In silico studies revealed the formation of an energetically stable complex between compound 5 and the EGFR crystal structure (min/- max binding affinities of -9.4|-8.0 kcal/mol, compared to the -7.71 kcal/mol for the native ligand). DISCUSSION: This preliminary study provides compelling data on synthesized derivatives, but more advanced testing is needed to assess their therapeutic value fully. Compared with earlier reports on related thiazolidinone scaffolds, the present derivatives exhibit improved potency, clearer selectivity, and mechanistic features consistent with EGFR inhibition and cytokine modulation.

conclusionThese findings validate (2-imino-4-oxo-1,3-thiazolidin-5-yl)acetic acid as a privileged core for cytotoxic lead generation and indicate that strategic substitution with either a tryptamine moiety (compound 5) or a 1,2,4-triazole ring (compound 7) is particularly advantageous. These compounds are promising EGFR-targeting anticancer candidates, warranting further investigation.

Indexed as

Antineoplastic AgentsMolecular Dynamics SimulationProtein Kinase InhibitorsThiazolidinesApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorErbB ReceptorsHumansMolecular Docking SimulationMolecular StructureStructure-Activity Relationship4-thiazolidinoneAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsThiazolidines4-thiazolidinoneanticancerbreast adenocarcinomacytotoxicitymolecular dockingselectivity index

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.